Home > Boards > US Listed > Computers - Hardware > Anixa Biosciences (ANIX)

Anixa Biosciences Presents Positive Data on its Liquid

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Paullee Member Profile
 
Followed By 16
Posts 2,349
Boards Moderated 0
Alias Born 11/25/03
160x600 placeholder
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 7/2/2020 6:11:41 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 7/2/2020 5:53:15 PM
Anixa Announces Strategic Program Realignment Focused on Advancement of its Therapeutic and Vaccine Pipeline PR Newswire (US) - 7/2/2020 5:00:00 PM
Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a) Edgar (US Regulatory) - 6/22/2020 5:07:36 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/17/2020 10:31:14 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/12/2020 10:48:45 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 6/9/2020 5:12:25 PM
Anixa Biosciences and OntoChem Have Synthesized Four Potential Covid-19 Drugs for Testing in Biological Assays PR Newswire (US) - 6/1/2020 8:30:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/4/2020 5:45:58 PM
Anixa Biosciences and OntoChem Announce Discovery of First Covid-19 Therapeutic Candidate PR Newswire (US) - 5/4/2020 6:45:00 AM
Anixa Biosciences Announces Publication of Peer-Reviewed Journal Article in Biomarker Insights Highlighting Cchek™ Liquid B... PR Newswire (US) - 4/23/2020 7:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/20/2020 4:07:03 PM
Anixa Biosciences and OntoChem Announce Collaboration to Develop Novel COVID-19 Therapeutics PR Newswire (US) - 4/20/2020 6:30:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 3/17/2020 3:47:01 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 3/12/2020 1:39:20 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 3/12/2020 10:27:22 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 3/10/2020 2:54:45 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 3/9/2020 5:11:58 PM
Anixa Biosciences Announces Presentation at AI and Big Data in Cancer Conference PR Newswire (US) - 3/2/2020 7:00:00 AM
Anixa Biosciences and Moffitt Cancer Center Announce Completion of Viral Vector Reformulation for CAR-T Program PR Newswire (US) - 2/12/2020 7:00:00 AM
Anixa Biosciences Announces Presentation at AACR Liquid Biopsies Conference PR Newswire (US) - 1/6/2020 7:00:00 AM
Anixa Biosciences to Present at Biotech Showcase 2020 PR Newswire (US) - 12/23/2019 7:00:00 AM
Anixa Biosciences Announces Commercial Launch of Cchek™ Prostate Cancer Confirmatory Test PR Newswire (US) - 12/16/2019 6:45:00 AM
Anixa Biosciences to Host Conference Call to Discuss Plans for 2020 PR Newswire (US) - 12/13/2019 5:45:00 PM
Anixa Biosciences Provides Update on CAR-T Program PR Newswire (US) - 12/13/2019 6:45:00 AM
Paullee   Monday, 12/03/18 08:38:50 AM
Re: None
Post # of 691 
Anixa Biosciences Presents Positive Data on its Liquid Biopsy for Early Detection of Breast Cancer at AACR Conference

PR Newswire PR NewswireDecember 3, 2018
SAN JOSE, Calif., Dec. 3, 2018 /PRNewswire/ -- Anixa Biosciences, Inc. (ANIX), a biotechnology company focused on using the body's immune system to fight cancer, presented the latest data from its ongoing study focusing on early detection of breast cancer, utilizing Cchek™, its artificial intelligence (AI) driven cancer detection technology, at the American Association of Cancer Research (AACR) Special Conference on Tumor Immunology and Immunotherapy. The conference is designed to integrate multidisciplinary facets of basic cancer immunology and immunotherapy to broaden the understanding of ways to harness the immune system to address cancer. The conference was held November 27–30, 2018 in Miami Beach, Florida.

Anixa Biosciences, Inc. (PRNewsfoto/Anixa Biosciences, Inc.)
Anixa Biosciences, Inc. (PRNewsfoto/Anixa Biosciences, Inc.)
More
Anixa presented data demonstrating the ability of Cchek™ to identify the presence of early stage breast cancer in a subject by using its AI technology to analyze a simple blood draw. The Cchek™ technology demonstrated a sensitivity of 89.3% when detecting early stage breast cancer (Stage I or II) and a specificity (the ability to correctly identify healthy subjects) of 94.7% when used to test blinded samples. Furthermore, Cchek™ was also able to detect the early stages of breast cancer (Stage 0) in subjects with biopsy-confirmed ductal carcinoma in situ (DCIS), a type of pre-cancerous/non-invasive breast lesion that often leads to invasive breast cancer, with 72% sensitivity. The presentation is available on Anixa's website, or it may be requested by sending an email to AACR-TII-2018@anixa.com and including your name, title, and contact information.

"We are pleased to have made our presentation titled, Combining the immunophenotyping of MDSCs and lymphocytes with artificial intelligence (AI) to predict early stage breast cancer, at the AACR Tumor Immunology and Immunotherapy conference. This data was focused on using our Cchek™ technology to detect breast cancer in its early stages, primarily stage I and II when the cancer is more easily treated. The majority of screening technologies currently used for breast cancer detection, such as mammography, have the ability to detect later stage breast malignancies rather successfully but have shown difficulty with earlier stages. A major challenge with mammography is the large number of false positives resulting in overtreatment and many unnecessary biopsies," stated Dr. Amit Kumar, President and CEO of Anixa Biosciences. "As our study continues, we hope to enable a better approach for identifying breast cancer as early as possible including even when a non-invasive breast cancer lesion is present, such as in the case of DCIS. We have previously announced that our initial commercial focus is on a prostate cancer test for which we will be meeting with the USFDA on December 17, 2018. We recently presented our latest prostate cancer data at the 33rd Annual Meeting of The Society for Immunotherapy of Cancer (SITC)," added Dr. Kumar.

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist